Linked Life Data

21660451

Source:http://linkedlifedata.com/resource/pubmed/id/21660451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2011-9-20
pubmed:abstractText
The high molecular weight melanoma-associated antigen (HMW-MAA) and the cytoplasmic melanoma-associated antigen (cyt-MAA/LGALS3BP) are expressed in melanoma. Their serum levels are increased in melanoma patients and correlate with clinical outcome. We investigated whether these molecules can serve as prognostic markers for neuroblastoma (NB) patients. Expression of cyt-MAA and HMW-MAA was evaluated by flow cytometry in NB cell lines, patients' neuroblasts ((FI)-NB), and short-term cultures of these latter cells (cNB). LGALS3BP gene expression was evaluated by RT-qPCR on (FI)-NB, cNB, and primary tumor specimens. Soluble HMW-MAA and cyt-MAA were tested by ELISA. Cyt-MAA and HMW-MAA were expressed in NB cell lines, cNB, and (FI)-NB samples. LGALS3BP gene expression was higher in primary tumors and cNB than in (FI)-NB samples. Soluble cyt-MAA, but not HMW-MAA, was detected in NB cell lines and cNBs supernatants. NB patients' serum levels of both antigens were higher than those of the healthy children. High cyt-MAA serum levels at diagnosis associated with higher incidence of relapse, independently from other known risk factors. In conclusion, both HMW-MAA and cyt-MAA antigens, and LGALS3BP gene, were expressed by NB cell lines and patients' neuroblasts, and both antigens' serum levels were increased in NB patients. Elevated serum levels of cyt-MAA at diagnosis correlated with relapse, supporting that cyt-MAA may serve as early serological biomarker to individuate patients at higher risk of relapse that may require a more careful follow-up, after being validated in a larger cohort of patients at different time-points during follow-up. Given its immunogenicity, cyt-MAA may also be a potential target for NB immunotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1432-0851
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1485-95
pubmed:meshHeading
pubmed-meshheading:21660451-Antigens, Neoplasm, pubmed-meshheading:21660451-Carrier Proteins, pubmed-meshheading:21660451-Cell Separation, pubmed-meshheading:21660451-Child, pubmed-meshheading:21660451-Child, Preschool, pubmed-meshheading:21660451-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:21660451-Female, pubmed-meshheading:21660451-Flow Cytometry, pubmed-meshheading:21660451-Glycoproteins, pubmed-meshheading:21660451-Humans, pubmed-meshheading:21660451-Infant, pubmed-meshheading:21660451-Kaplan-Meier Estimate, pubmed-meshheading:21660451-Male, pubmed-meshheading:21660451-Neuroblastoma, pubmed-meshheading:21660451-Prognosis, pubmed-meshheading:21660451-Proportional Hazards Models, pubmed-meshheading:21660451-Recurrence, pubmed-meshheading:21660451-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:21660451-Tumor Markers, Biological
pubmed:year
2011
pubmed:articleTitle
Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.
pubmed:affiliation
Laboratory of Oncology, G. Gaslini Children's Hospital, Largo G. Gaslini 5, 16148 Genoa, Italy. fabiomorandi@ospedale-gaslini.ge.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't